Strengths of our study include the use of a well-characterized clinical cohort of contemporary radical prostatectomy patients, expert pathology review, and microdissection of tumor and NT, use of a hard clinical endpoint (clinical tumor recurrence and not biochemical failure), an unbiased approach to gene selection after initial identification of genes of interest, a pre-specified analysis plan, and use of T2:ERG fusion status to rule out contamination of NT by tumor. Here, ERG is linked to neoplasm.